ISSN:
1432-0584
Keywords:
BMT
;
Recombinant human erythropoietin
;
Regeneration of erythropoiesis
;
Erythrocyte transfusion
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary The hematologic effects of recombinant human erythropoietin after allogeneic bone marrow transplantation (BMT) were studied. Nineteen patients received 150 U/kg/day of C127 mouse-cell-derived recombinant human erythropoietin (rHu EPO) as a daily continuous intravenous infusion until hematocrit exceeded 35%. These data were compared with a treatment-matched historical control group of 43 patients. RHu EPO-treated patients recovered erythropoiesis more rapidly and became independent from erythrocyte transfusions after a median of 17 days, which was 7 days earlier than the control patients.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01695863
Permalink